Is Ruxolitinib Tablets/Ruxolitinib a Class A drug?

Ruxolitinib tablets/Ruxolitinib (Ruxolitinib) is an anti-tumor drug. It inhibits tumor growth by inhibiting cell proliferation. After this drug is launched in China, it is mainly used to treat adult patients with intermediate-risk or high-risk primary myelofibrosis (PMF), myelofibrosis secondary to polycythemia vera (PPV-MF), or myelofibrosis secondary to essential thrombocythemia (PET-MF) to treat disease-related splenomegaly or disease-related symptoms. It is also used to treat acute graft-versus-host disease (aGVHD) in patients who have an inadequate response to glucocorticoids or other systemic treatments and are aged 12 years and older.

Ruxolitinib is a first-in-class JAK1/JAK2 inhibitor. Novartis is responsible for the commercialization of the tablets outside the EU under the trade name Jakavi, while Incyte is responsible for the development and commercialization of ruxolitinib in the United States under the tradename Jakafi. Ruxolitinib tablets were first approved for marketing by the National Medical Products Administration through the priority review process in March 2017.

Class A drugs refer to drugs that are basically unified across the country and can ensure the basic needs of clinical treatment. These drugs usually have accurate effects, are widely used, and have low prices or treatment costs. Among over-the-counter drugs, Class A drugs are marked with a red OTC sign and must be sold in pharmacies. However, there is currently no direct information indicating whether ruxolitinib tablets are a Class A drug. As a prescription drug, it is mainly used to treat specific myelofibrosis diseases, and its use requires a doctor's prescription and guidance. Therefore, ruxolitinib tablets may not be classified as over-the-counter drugs and cannot be directly classified as a Class A drug.